Blog

Category Archives: Press Releases

Now Introducing the MNGenome®

MNG is proud to announce the launch of the MNGenome®. This new test sequences the entire human genome, making it our most comprehensive clinical diagnostic test ever. The MNGenome® provides greater sensitivity than whole exome sequencing, since approximately 20% of known pathogenic variants are outside the exon boundaries. The MNGenome® is a comprehensive approach to diagnosis when faced with challenging phenotypes, and no diagnosis with CMA and whole exome sequencing.

To read the full press release, click here.

 

MNG Expands Global Reach with Several New Distributors

MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, and technical leadership in their respective markets.
“This is just the start of MNG’s expansion strategy for global markets since we brought on dedicated business development talent to address this market opportunity late in 2017,” noted MNG’s President & CEO Terry Conrad. “We have additional pending agreements in different phases of development across the globe and are active in seeking additional partnerships in the Pharmaceutical, Biotech and University research arenas. MNG has a leadership position in neurogenetic and complex biochemical testing and our products and experience are trusted by research and development interests who are focused in neurology.”

To read the full press release, click here.

MNG Laboratories Announces New Scientific Advisory Board Members

(from left to right): Kevin Campbell, Terry Conrad, Peter Nagy, Val Sheffield, Uta Francke, Ben Tycko, Howard Worman, Keith Hyland
MNG’s Scientific Advisory Board

MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of five distinguished members of the genetic community to its Scientific Advisory Board. All members have recognized leadership roles in the genetic/diagnostic testing field and will assist MNG Laboratories by providing critical scientific support to MNG’s existing and future diagnostics business.

To read the full press release, click here.

MNG Laboratories Welcomes Humberto Huerta, Sr. Director of Business Development

Humberto Huerta
Senior Director of Business Development

MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of Humberto Huerta as Senior Director of Business Development. Mr. Huerta brings 27 years of experience in the genetic/diagnostic testing field and will lead MNG’s expansion into the global neurogenetic testing field.

To read the full press release, click here.

MNG Laboratories is Now CAP and CLIA Accredited

On September 26, 2016, MNG Laboratories announced its accreditation from the College of American Pathologists (CAP). CAP aims to improve patient safety by advancing the quality of pathology and laboratory services through education, standard setting, and ensuring laboratories meet or exceed regulatory requirement. As of now, CAP accredits more than 7,600 laboratories globally. Read more about this exciting milestone for MNG Laboratories here.